FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PPARG-CDKAL1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PPARG-CDKAL1
FusionPDB ID: 67348
FusionGDB2.0 ID: 67348
HgeneTgene
Gene symbol

PPARG

CDKAL1

Gene ID

5468

54901

Gene nameperoxisome proliferator activated receptor gammaCDK5 regulatory subunit associated protein 1 like 1
SynonymsCIMT1|GLM1|NR1C3|PPARG1|PPARG2|PPARgamma-
Cytomap

3p25.2

6p22.3

Type of geneprotein-codingprotein-coding
Descriptionperoxisome proliferator-activated receptor gammaPPAR-gammanuclear receptor subfamily 1 group C member 3peroxisome proliferator-activated nuclear receptor gamma variant 1threonylcarbamoyladenosine tRNA methylthiotransferasetRNA-t(6)A37 methylthiotransferase
Modification date2020032920200322
UniProtAcc

P37231

Main function of 5'-partner protein: FUNCTION: Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity). {ECO:0000250|UniProtKB:P37238, ECO:0000269|PubMed:16150867, ECO:0000269|PubMed:20829347, ECO:0000269|PubMed:23525231, ECO:0000269|PubMed:9065481}.; FUNCTION: (Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein. {ECO:0000269|PubMed:25504154}.

Q5VV42

Main function of 5'-partner protein: FUNCTION: Catalyzes the methylthiolation of N6-threonylcarbamoyladenosine (t(6)A), leading to the formation of 2-methylthio-N6-threonylcarbamoyladenosine (ms(2)t(6)A) at position 37 in tRNAs that read codons beginning with adenine. {ECO:0000250|UniProtKB:Q91WE6}.
Ensembl transtripts involved in fusion geneENST idsENST00000287820, ENST00000309576, 
ENST00000397010, ENST00000397012, 
ENST00000397015, ENST00000397026, 
ENST00000397000, ENST00000539812, 
ENST00000476517, ENST00000274695, 
ENST00000378610, ENST00000378624, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score7 X 9 X 5=31523 X 22 X 8=4048
# samples 1330
** MAII scorelog2(13/315*10)=-1.27684020535882
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(30/4048*10)=-3.75417488419843
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PPARG [Title/Abstract] AND CDKAL1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PPARG [Title/Abstract] AND CDKAL1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PPARG(12458653)-CDKAL1(20649524), # samples:2
Anticipated loss of major functional domain due to fusion event.PPARG-CDKAL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PPARG-CDKAL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PPARG-CDKAL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PPARG-CDKAL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgenePPARG

GO:0000122

negative regulation of transcription by RNA polymerase II

12700342

HgenePPARG

GO:0006919

activation of cysteine-type endopeptidase activity involved in apoptotic process

18293083

HgenePPARG

GO:0007165

signal transduction

9568716

HgenePPARG

GO:0010742

macrophage derived foam cell differentiation

26504087

HgenePPARG

GO:0010745

negative regulation of macrophage derived foam cell differentiation

19114110

HgenePPARG

GO:0010871

negative regulation of receptor biosynthetic process

12700342

HgenePPARG

GO:0010887

negative regulation of cholesterol storage

19114110

HgenePPARG

GO:0010891

negative regulation of sequestering of triglyceride

12700342

HgenePPARG

GO:0016525

negative regulation of angiogenesis

28566713

HgenePPARG

GO:0030224

monocyte differentiation

9568716

HgenePPARG

GO:0032526

response to retinoic acid

16239304

HgenePPARG

GO:0042953

lipoprotein transport

9568716

HgenePPARG

GO:0043537

negative regulation of blood vessel endothelial cell migration

28566713

HgenePPARG

GO:0045713

low-density lipoprotein particle receptor biosynthetic process

9568716

HgenePPARG

GO:0045944

positive regulation of transcription by RNA polymerase II

9568715|12700342|16239304|17611579

HgenePPARG

GO:0048469

cell maturation

9568716

HgenePPARG

GO:0048662

negative regulation of smooth muscle cell proliferation

20622039

HgenePPARG

GO:0051091

positive regulation of DNA-binding transcription factor activity

18293083

HgenePPARG

GO:0061614

pri-miRNA transcription by RNA polymerase II

28566713

HgenePPARG

GO:0071404

cellular response to low-density lipoprotein particle stimulus

9568716

HgenePPARG

GO:1904706

negative regulation of vascular smooth muscle cell proliferation

28522568



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:12458653/chr6:20649524)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PPARG (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CDKAL1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000397010PPARGchr312458653+ENST00000274695CDKAL1chr620649524+438915703843023879
ENST00000397010PPARGchr312458653+ENST00000378624CDKAL1chr620649524+432615703842960858
ENST00000397010PPARGchr312458653+ENST00000378610CDKAL1chr620649524+438915703843023879
ENST00000309576PPARGchr312458653+ENST00000274695CDKAL1chr620649524+424214232372876879
ENST00000309576PPARGchr312458653+ENST00000378624CDKAL1chr620649524+417914232372813858
ENST00000309576PPARGchr312458653+ENST00000378610CDKAL1chr620649524+424214232372876879
ENST00000397015PPARGchr312458653+ENST00000274695CDKAL1chr620649524+412713081222761879
ENST00000397015PPARGchr312458653+ENST00000378624CDKAL1chr620649524+406413081222698858
ENST00000397015PPARGchr312458653+ENST00000378610CDKAL1chr620649524+412713081222761879
ENST00000397012PPARGchr312458653+ENST00000274695CDKAL1chr620649524+437815593733012879
ENST00000397012PPARGchr312458653+ENST00000378624CDKAL1chr620649524+431515593732949858
ENST00000397012PPARGchr312458653+ENST00000378610CDKAL1chr620649524+437815593733012879
ENST00000397026PPARGchr312458653+ENST00000274695CDKAL1chr620649524+440615873833040885
ENST00000397026PPARGchr312458653+ENST00000378624CDKAL1chr620649524+434315873832977864
ENST00000397026PPARGchr312458653+ENST00000378610CDKAL1chr620649524+440615873833040885
ENST00000287820PPARGchr312458653+ENST00000274695CDKAL1chr620649524+421013911212844907
ENST00000287820PPARGchr312458653+ENST00000378624CDKAL1chr620649524+414713911212781886
ENST00000287820PPARGchr312458653+ENST00000378610CDKAL1chr620649524+421013911212844907

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000397010ENST00000274695PPARGchr312458653+CDKAL1chr620649524+0.0003402690.9996598
ENST00000397010ENST00000378624PPARGchr312458653+CDKAL1chr620649524+0.000339010.99966097
ENST00000397010ENST00000378610PPARGchr312458653+CDKAL1chr620649524+0.0003402690.9996598
ENST00000309576ENST00000274695PPARGchr312458653+CDKAL1chr620649524+0.0003999120.9996001
ENST00000309576ENST00000378624PPARGchr312458653+CDKAL1chr620649524+0.0004007810.9995993
ENST00000309576ENST00000378610PPARGchr312458653+CDKAL1chr620649524+0.0003999120.9996001
ENST00000397015ENST00000274695PPARGchr312458653+CDKAL1chr620649524+0.0003896320.99961036
ENST00000397015ENST00000378624PPARGchr312458653+CDKAL1chr620649524+0.0003911170.99960893
ENST00000397015ENST00000378610PPARGchr312458653+CDKAL1chr620649524+0.0003896320.99961036
ENST00000397012ENST00000274695PPARGchr312458653+CDKAL1chr620649524+0.0002876630.9997123
ENST00000397012ENST00000378624PPARGchr312458653+CDKAL1chr620649524+0.0002828830.99971706
ENST00000397012ENST00000378610PPARGchr312458653+CDKAL1chr620649524+0.0002876630.9997123
ENST00000397026ENST00000274695PPARGchr312458653+CDKAL1chr620649524+0.0011936870.99880636
ENST00000397026ENST00000378624PPARGchr312458653+CDKAL1chr620649524+0.0011961980.99880385
ENST00000397026ENST00000378610PPARGchr312458653+CDKAL1chr620649524+0.0011936870.99880636
ENST00000287820ENST00000274695PPARGchr312458653+CDKAL1chr620649524+0.0005605370.9994394
ENST00000287820ENST00000378624PPARGchr312458653+CDKAL1chr620649524+0.0007042410.9992957
ENST00000287820ENST00000378610PPARGchr312458653+CDKAL1chr620649524+0.0005605370.9994394

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PPARG-CDKAL1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PPARGchr312458653CDKAL1chr6206495241308395DLAIFIAVIILSGENASDADLWLLNS
PPARGchr312458653CDKAL1chr6206495241391423DLAIFIAVIILSGENASDADLWLLNS
PPARGchr312458653CDKAL1chr6206495241423395DLAIFIAVIILSGENASDADLWLLNS
PPARGchr312458653CDKAL1chr6206495241559395DLAIFIAVIILSGENASDADLWLLNS
PPARGchr312458653CDKAL1chr6206495241570395DLAIFIAVIILSGENASDADLWLLNS
PPARGchr312458653CDKAL1chr6206495241587401DLAIFIAVIILSGENASDADLWLLNS

Top

Potential FusionNeoAntigen Information of PPARG-CDKAL1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PPARG-CDKAL1_12458653_20649524.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PPARG-CDKAL1chr312458653chr6206495241391HLA-B44:03GENASDADLW0.99820.93931222
PPARG-CDKAL1chr312458653chr6206495241391HLA-B39:08GENASDADL0.23390.73831221
PPARG-CDKAL1chr312458653chr6206495241391HLA-B44:10GENASDADLW0.72350.55731222
PPARG-CDKAL1chr312458653chr6206495241391HLA-B40:04GENASDADL0.98260.62971221
PPARG-CDKAL1chr312458653chr6206495241391HLA-B41:03GENASDADL0.2160.50761221
PPARG-CDKAL1chr312458653chr6206495241391HLA-B44:07GENASDADLW0.99820.93931222
PPARG-CDKAL1chr312458653chr6206495241391HLA-B44:26GENASDADLW0.99820.93931222
PPARG-CDKAL1chr312458653chr6206495241391HLA-B44:13GENASDADLW0.99820.93931222

Top

Potential FusionNeoAntigen Information of PPARG-CDKAL1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PPARG-CDKAL1_12458653_20649524.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PPARG-CDKAL1chr312458653chr6206495241391DRB1-0102IAVIILSGENASDAD520
PPARG-CDKAL1chr312458653chr6206495241391DRB1-0102FIAVIILSGENASDA419
PPARG-CDKAL1chr312458653chr6206495241391DRB1-0111FIAVIILSGENASDA419
PPARG-CDKAL1chr312458653chr6206495241391DRB1-0411IAVIILSGENASDAD520
PPARG-CDKAL1chr312458653chr6206495241391DRB1-0467IAVIILSGENASDAD520
PPARG-CDKAL1chr312458653chr6206495241391DRB1-0491IAVIILSGENASDAD520
PPARG-CDKAL1chr312458653chr6206495241391DRB1-1410IAVIILSGENASDAD520

Top

Fusion breakpoint peptide structures of PPARG-CDKAL1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
690AVIILSGENASDADPPARGCDKAL1chr312458653chr6206495241391

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PPARG-CDKAL1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN690AVIILSGENASDAD-7.15543-7.26883
HLA-B14:023BVN690AVIILSGENASDAD-4.77435-5.80965
HLA-B52:013W39690AVIILSGENASDAD-6.80875-6.92215
HLA-B52:013W39690AVIILSGENASDAD-4.20386-5.23916
HLA-A11:014UQ2690AVIILSGENASDAD-7.5194-8.5547
HLA-A11:014UQ2690AVIILSGENASDAD-6.9601-7.0735
HLA-A24:025HGA690AVIILSGENASDAD-7.52403-7.63743
HLA-A24:025HGA690AVIILSGENASDAD-5.82433-6.85963
HLA-B27:056PYJ690AVIILSGENASDAD-3.28285-4.31815
HLA-B44:053DX8690AVIILSGENASDAD-5.91172-6.94702
HLA-B44:053DX8690AVIILSGENASDAD-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of PPARG-CDKAL1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PPARG-CDKAL1chr312458653chr6206495241221GENASDADLGAGAAAATGCATCCGATGCAGATTTAT
PPARG-CDKAL1chr312458653chr6206495241222GENASDADLWGAGAAAATGCATCCGATGCAGATTTATGGC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
PPARG-CDKAL1chr312458653chr620649524419FIAVIILSGENASDATTATTGCTGTCATTATTCTCAGTGGAGAAAATGCATCCGATGCAG
PPARG-CDKAL1chr312458653chr620649524520IAVIILSGENASDADTTGCTGTCATTATTCTCAGTGGAGAAAATGCATCCGATGCAGATT

Top

Information of the samples that have these potential fusion neoantigens of PPARG-CDKAL1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BLCAPPARG-CDKAL1chr312458653ENST00000287820chr620649524ENST00000274695TCGA-DK-A1AD-01A

Top

Potential target of CAR-T therapy development for PPARG-CDKAL1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneCDKAL1chr3:12458653chr6:20649524ENST00000274695316556_5780580.0TransmembraneHelical
TgeneCDKAL1chr3:12458653chr6:20649524ENST00000378610114556_5780580.0TransmembraneHelical
TgeneCDKAL1chr3:12458653chr6:20649524ENST00000378624214556_5780489.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PPARG-CDKAL1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PPARG-CDKAL1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgenePPARGC0011860Diabetes Mellitus, Non-Insulin-Dependent6CTD_human;GENOMICS_ENGLAND
HgenePPARGC0238463Papillary thyroid carcinoma4ORPHANET
HgenePPARGC0002152Alloxan Diabetes3CTD_human
HgenePPARGC0002395Alzheimer's Disease3CTD_human
HgenePPARGC0011265Presenile dementia3CTD_human
HgenePPARGC0011853Diabetes Mellitus, Experimental3CTD_human
HgenePPARGC0020538Hypertensive disease3CTD_human
HgenePPARGC0021655Insulin Resistance3CTD_human
HgenePPARGC0022660Kidney Failure, Acute3CTD_human
HgenePPARGC0028754Obesity3CTD_human;GENOMICS_ENGLAND;UNIPROT
HgenePPARGC0035126Reperfusion Injury3CTD_human
HgenePPARGC0038433Streptozotocin Diabetes3CTD_human
HgenePPARGC0276496Familial Alzheimer Disease (FAD)3CTD_human
HgenePPARGC0494463Alzheimer Disease, Late Onset3CTD_human
HgenePPARGC0546126Acute Confusional Senile Dementia3CTD_human
HgenePPARGC0750900Alzheimer's Disease, Focal Onset3CTD_human
HgenePPARGC0750901Alzheimer Disease, Early Onset3CTD_human
HgenePPARGC0920563Insulin Sensitivity3CTD_human
HgenePPARGC1565662Acute Kidney Insufficiency3CTD_human
HgenePPARGC1720861Familial Partial Lipodystrophy, Type 33CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgenePPARGC2609414Acute kidney injury3CTD_human
HgenePPARGC0021368Inflammation2CTD_human
HgenePPARGC0022116Ischemia2CTD_human
HgenePPARGC0024623Malignant neoplasm of stomach2CTD_human
HgenePPARGC0025202melanoma2CTD_human
HgenePPARGC0030297Pancreatic Neoplasm2CTD_human
HgenePPARGC0038356Stomach Neoplasms2CTD_human
HgenePPARGC0346647Malignant neoplasm of pancreas2CTD_human
HgenePPARGC1708349Hereditary Diffuse Gastric Cancer2CTD_human
HgenePPARGC0001418Adenocarcinoma1CTD_human
HgenePPARGC0004153Atherosclerosis1CTD_human
HgenePPARGC0004763Barrett Esophagus1CTD_human
HgenePPARGC0007102Malignant tumor of colon1CTD_human;UNIPROT
HgenePPARGC0009375Colonic Neoplasms1CTD_human
HgenePPARGC0009402Colorectal Carcinoma1CTD_human
HgenePPARGC0009404Colorectal Neoplasms1CTD_human
HgenePPARGC0010346Crohn Disease1CTD_human
HgenePPARGC0011849Diabetes Mellitus1CTD_human
HgenePPARGC0011859Lipoatrophic Diabetes Mellitus1ORPHANET
HgenePPARGC0011881Diabetic Nephropathy1CTD_human
HgenePPARGC0017658Glomerulonephritis1CTD_human
HgenePPARGC0017667Nodular glomerulosclerosis1CTD_human
HgenePPARGC0018801Heart failure1CTD_human
HgenePPARGC0018802Congestive heart failure1CTD_human
HgenePPARGC0023212Left-Sided Heart Failure1CTD_human
HgenePPARGC0023645Lichen planus follicularis1GENOMICS_ENGLAND
HgenePPARGC0023794Lipoidosis1CTD_human
HgenePPARGC0023903Liver neoplasms1CTD_human
HgenePPARGC0025517Metabolic Diseases1CTD_human
HgenePPARGC0027746Nerve Degeneration1CTD_human
HgenePPARGC0029408Degenerative polyarthritis1CTD_human
HgenePPARGC0030246Pustulosis of Palms and Soles1CTD_human
HgenePPARGC0030625Passive Cutaneous Anaphylaxis1GENOMICS_ENGLAND
HgenePPARGC0033860Psoriasis1CTD_human
HgenePPARGC0035078Kidney Failure1CTD_human
HgenePPARGC0038525Subarachnoid Hemorrhage1CTD_human
HgenePPARGC0040136Thyroid Neoplasm1CTD_human
HgenePPARGC0079772T-Cell Lymphoma1CTD_human
HgenePPARGC0085278Antiphospholipid Syndrome1CTD_human
HgenePPARGC0085413Polycystic Kidney, Autosomal Dominant1CTD_human
HgenePPARGC0086743Osteoarthrosis Deformans1CTD_human
HgenePPARGC0086873Pseudopelade1GENOMICS_ENGLAND
HgenePPARGC0151468Thyroid Gland Follicular Adenoma1CTD_human
HgenePPARGC0156147Crohn's disease of large bowel1CTD_human
HgenePPARGC0205641Adenocarcinoma, Basal Cell1CTD_human
HgenePPARGC0205642Adenocarcinoma, Oxyphilic1CTD_human
HgenePPARGC0205643Carcinoma, Cribriform1CTD_human
HgenePPARGC0205644Carcinoma, Granular Cell1CTD_human
HgenePPARGC0205645Adenocarcinoma, Tubular1CTD_human
HgenePPARGC0206726gliosarcoma1ORPHANET
HgenePPARGC0221032Familial generalized lipodystrophy1ORPHANET
HgenePPARGC0221406Pituitary-dependent Cushing's disease1CTD_human
HgenePPARGC0235527Heart Failure, Right-Sided1CTD_human
HgenePPARGC0236811Chronobiology Disorders1CTD_human
HgenePPARGC0242339Dyslipidemias1CTD_human
HgenePPARGC0242488Acute Lung Injury1CTD_human
HgenePPARGC0267380Crohn's disease of the ileum1CTD_human
HgenePPARGC0270192Perinatal Subarachnoid Hemorrhage1CTD_human
HgenePPARGC0271694Familial partial lipodystrophy1CTD_human
HgenePPARGC0282548Leukostasis1CTD_human
HgenePPARGC0334588Giant Cell Glioblastoma1ORPHANET
HgenePPARGC0345904Malignant neoplasm of liver1CTD_human
HgenePPARGC0472383Subarachnoid Hemorrhage, Spontaneous1CTD_human
HgenePPARGC0525045Mood Disorders1PSYGENET
HgenePPARGC0549473Thyroid carcinoma1CTD_human
HgenePPARGC0598784Dyslipoproteinemias1CTD_human
HgenePPARGC0678202Regional enteritis1CTD_human
HgenePPARGC0751220Inappropriate ACTH Secretion Syndrome1CTD_human
HgenePPARGC0751530Subarachnoid Hemorrhage, Aneurysmal1CTD_human
HgenePPARGC0795688Subarachnoid Hemorrhage, Intracranial1CTD_human
HgenePPARGC0813142Circadian Rhythm Disorders1CTD_human
HgenePPARGC0887800Psychogenic Inversion of Circadian Rhythm1CTD_human
HgenePPARGC0887850Polycystic Kidney, Type 1 Autosomal Dominant Disease1CTD_human
HgenePPARGC0949272IIeocolitis1CTD_human
HgenePPARGC1258085Barrett Epithelium1CTD_human
HgenePPARGC1563937Atherogenesis1CTD_human
HgenePPARGC1565489Renal Insufficiency1CTD_human
HgenePPARGC1704377Bright Disease1CTD_human
HgenePPARGC1720859Familial Partial Lipodystrophy, Type 11CTD_human
HgenePPARGC1720860Familial Partial Lipodystrophy, Type 21CTD_human
HgenePPARGC1959583Myocardial Failure1CTD_human
HgenePPARGC1961112Heart Decompensation1CTD_human
HgenePPARGC2239176Liver carcinoma1CTD_human
HgenePPARGC2751306Polycystic kidney disease, type 21CTD_human
HgenePPARGC2931367Thyroid cancer, follicular1CTD_human
HgenePPARGC2936846Scarring alopecia1GENOMICS_ENGLAND